Mimix™ Non-Small Cell Lung Cancer Panel Negative Control, ctDNA Reference Standard

The Non-Small Cell Lung Cancer ctDNA Panel Reference Standard negative control is well characterized, cell line-derived control material manufactured under ISO 9001:2015 and ISO 13485:2016 that is tested negative for 22 variants across 7 genes clinically relevant to NSCLCs.

The Non-Small Cell Lung Cancer ctDNA Panel reference standard negative control is thoroughly tested and confirmed to be negative for all the 22 clinically relevant mutations using ddPCR. This cell line-derived panel is manufactured under ISO 9001:2015 and ISO 13485:2016. This panel can be used as a negative control or to dilute the allele frequency of the NSCLC ctDNA panel reference standard - HD844 further enabling validation of MRD.

Technical data

Format: ctDNA

Genes covered: EGFR, KRAS, BRAF, MET, ERBB2, PIK3CA, NRAS

Allelic frequencies: 0%

Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0

Product information

Fragment size: 160 bp

Unit size: 350 ng per vial

Concentration: 20 ng/µL

Verified mutations:

General information

Storage: 4°C

Expiration: See all product shelf life information

Intended use: For assay developers, molecular diagnostic labs (Research use only)

Quality control

Fragmentation size: D1000 DNA ScreenTape assay

Allelic frequency: Droplet Digital™ PCR

Quantification: Qubit® dsDNA BR assay (Invitrogen)

Intended use: For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.

References

• Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26(7):1421-1427. doi:10.1093/annonc/mdv186

Selection guide